HBV Disease Progression
AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- Details
- Category: Liver Cancer/HCC
- Published on Wednesday, 01 November 2017 00:00
- Written by Liz Highleyman
People with hepatitis B virus (HBV) who took an aspirin a day -- often recommended to help prevent cardiovascular disease -- had a lower risk of developing liver cancer, according to a study from Taiwan presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- Details
- Category: Decompensation & ESLD
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 20 April 2017 00:00
- Written by Liz Highleyman
The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.
More Articles...
- AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?
- AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer
- Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
Web Design and Development by